Eledon Pharmaceuticals, Inc. reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting taking place in Philadelphia, PA from November 2-5, 2023. Aggregate mean estimated glomerular filtration rate (eGFR) -- a measure of kidney function -- was above 70 mL/min/1.73m(2) at all reported time points after day 90.

Historical studies have reported average eGFRs generally in the low 50 mL/min/1. 73m(2) range during the first year after kidney transplant using standard of care. One participant has completed the study with an eGFR of 91 at one year (day 374) and is now enrolled in a Phase 2 open-label extension (OLE) study, which will evaluate the long-term safety, pharmacokinetics, and efficacy of tegoprubart in participants who have completed one year of treatment in either the ongoing Phase 1b or Phase 2 BESTOW study. The Phase 1b open-label study has enrolled 11 participants who underwent kidney transplantation in Canada, Australia, and the United Kingdom.

The webcast will be archived on the website following the completion of the call.